Skip to main content

Table 1 Clinical characteristics of control donors and hospitalized patients with COVID-19

From: Transcriptional landscape of circulating platelets from patients with COVID-19 reveals key subnetworks and regulators underlying SARS-CoV-2 infection: implications for immunothrombosis

  Control donors COVID-19 patients P-value
(n = 8) (n = 10)
Age, years 47.25 (± 8.31) 45.80 (± 13.76) 0.797a
Gender, male 4 (50%) 6 (60%) 0.520b
Comorbidities  
Hypertension 0 (0%) 3 (30%)  
Diabetes 0 (0%) 2 (20%)  
Cancer 0 (0%) 1 (10%)  
Hyperlipidemia 3 (37.5%) 0 (0%)  
Heart disease 0 (0%) 0 (0%)  
DVT 0 (0%) 0 (0%)  
Symptom  
Fever 0 (0%) 8 (80%)  
Cough 0 (0%) 8 (80%)  
Expectoration 0 (0%) 5 (50%)  
Sore throat 0 (0%) 3 (30%)  
Fatigue 0 (0%) 1 (10%)  
Muscle ache 0 (0%) 2 (20%)  
Chest tightness 0 (0%) 0 (0%)  
Nausea 0 (0%) 1 (10%)  
Diarrhea 0 (0%) 0 (0%)  
Physical signs  
Respiratory rate   20 (18–20)  
Heart rate   85 (75–92)  
Laboratory findings on admission
CRP, mg/dL 1.41 (± 1.78) 22.51 (± 25.65) 0.029a
Leukocytes, × 109/L 5.39 (± 1.34) 4.85 (± 1.54) 0.440a
Neutrophils, × 109/L 3.10 (± 0.85) 3.00 (± 1.33) 0.846a
Lymphocytes, × 109/L 1.88 (± 0.66) 1.27 (± 0.28) 0.037a
Platelet count, × 109/L 294.25 (± 44.52) 212.40 (± 70.70) 0.009a
MPV, fl 10.06 (± 0.81) 9.78 (± 0.51) 0.407a
PT, S 12.31 (± 0.75) 13.73 (± 0.25) 0.399a
APTT, S 36.40 (± 4.19) 45.47 (± 5.17) 0.001a
Fibrinogen, mg/Dl 2.86 (± 0.54) 4.76 (± 0.87)  < 0.001a
ALT, U/L 21.25 (± 10.47) 26.70 (± 5.76) 0.215a
Creatinine, μmol/L 60.34 (± 12.74) 66.75 (± 21.00) 0.440a
  1. DVT, deep vein thrombosis; CRP, C reactive protein; MPV, mean platelet volume; PT, prothrombin time; APTT, activated partial thromboplastin time; ALT, alanine aminotransferase
  2. a Two-tailed Student T test
  3. b Chi-square test